Showing results 1 to 6 of 6
Issue DateTitleAuthor(s)
17-Nov-2011Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemiasNicolini, F.E.; Basak, G.W.; Soverini, S.; Martinelli, G.; Mauro, M.J.; Müller, M.C.; Hochhaus, A.; Chuah, C. ; Dufva, I.H.; Rege-Cambrin, G.; Saglio, G.; Michallet, M.; Labussière, H.; Morisset, S.; Hayette, S.; Etienne, G.; Olavarria, E.; Zhou, W.; Peter, S.; Apperley, J.F.; Cortes, J.
2014Bilineal T lymphoblastic and myeloid blast transformation in chronic myeloid leukemia with TP53 mutation-an uncommon presentation in adultsKrishnan, S.; Sabai, K.; Chuah, C. ; Tan, S.Y.
19-Jun-2018BIM Deletion Polymorphism Profiling Complements Prognostic Values of Risk Scores in Imatinib-treated Asian Chronic Myeloid Leukemia PatientsHein Than; Weng Kit Lye ; Colin Sng; John Allen, S. ; Tiong Ong ; Charles Chuah 
2014Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibitionNg K.P. ; Manjeri A. ; Lee K.L. ; Huang W. ; Tan S.Y. ; Chuah C.T.H. ; Poellinger L. ; Ong S.T. 
2018The arginase inhibitor N ? -hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional targetNg K.P. ; Manjeri A. ; Lee L.M. ; Chan Z.E. ; Tan C.Y.; Tan Q.D. ; Majeed A. ; Lee K.L. ; Chuah C. ; Suda T. ; Ong S.T. 
2017The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemiaRauzan M. ; Chuah C.T.H. ; Ko T.K. ; Tiong Ong S.